Latest news with #MarksansPharmaLimited
Business Upturn
11 hours ago
- Business
- Business Upturn
Marksans Pharma's UK subsidiary Relonchem secures marketing authorization from MHRA for Metformin tablets
Marksans Pharma Limited (NSE: MARKSANS, BSE: 524404) announced that its wholly owned UK-based subsidiary, Relonchem Limited, has received Marketing Authorization from the UK Medicines and Healthcare products Regulatory Agency (MHRA) for three key anti-diabetic products. The approvals cover: Metformin Hydrochloride Relonchem 500 mg Prolonged Release Tablets Metformin Hydrochloride Relonchem 750 mg Prolonged Release Tablets Metformin Hydrochloride Relonchem 1000 mg Prolonged Release Tablets Metformin is among the most widely prescribed medications for the treatment of type 2 diabetes, playing a crucial role in blood sugar management. With this authorization, Relonchem will be able to expand its presence in the UK market and further strengthen Marksans Pharma's position in the global anti-diabetic segment. Headquartered in Mumbai, Marksans Pharma operates manufacturing facilities in India, the USA, and the UK, all of which are approved by global regulators including USFDA, UKMHRA, and TGA. The company has a diversified product portfolio spanning cardiovascular, central nervous system, anti-diabetic, pain management, gastroenterology, and anti-allergy therapies. Ahmedabad Plane Crash Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at
Business Upturn
08-08-2025
- Business
- Business Upturn
Marksans Pharma subsidiary gets USFDA final approval for 20 mg Omeprazole Delayed-Release Tablets
Marksans Pharma Limited has announced the final approval of the company's wholly owned subsidiary, Marksans Pharma Inc., for its Abbreviated New Drug Application (ANDA) for Omeprazole Delayed-Release Tablets, 20 mg, as an over-the-counter (OTC) product. In its statement, the company said, 'Marksans Pharma Limited hereby announces the final approval of the Company's wholly owned subsidiary Marksans Pharma Inc.'s Abbreviated New Drug Application (ANDA) for Omeprazole Delayed-Release Tablets, 20 mg (OTC).' The product, according to the filing, 'is bioequivalent to the reference listed drug (RLD), Prilosec Delayed-Release Tablets, 20 mg (OTC), of AstraZeneca Pharmaceuticals LP, NDA – 021229.' Marksans Pharma also noted, 'Omeprazole is used to treat heartburn and certain other conditions caused by too much acid in the stomach.' This includes conditions where reducing stomach acid can help relieve discomfort and prevent further complications. Ahmedabad Plane Crash Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at
Business Upturn
19-06-2025
- Business
- Business Upturn
Marksans Pharma's UK subsidiary secures approval for Oxybutynin Hydrochloride oral solution
By Aditya Bhagchandani Published on June 19, 2025, 09:14 IST Marksans Pharma Limited announced today that its wholly owned UK-based subsidiary, Relonchem Limited, has received Marketing Authorization for Oxybutynin Hydrochloride 2.5mg/5ml Oral Solution from the UK's Medicines & Healthcare Products Regulatory Agency (MHRA). The product, used primarily for treating overactive bladder and urinary incontinence, expands Marksans' offering in the urology therapeutic segment and strengthens its European portfolio. The company, headquartered in Mumbai, manufactures and markets generic pharmaceutical formulations globally, with facilities in India, the US, and the UK—approved by regulatory bodies including the USFDA, UKMHRA, and Australia's TGA. 'This approval further reinforces our commitment to expanding our presence in regulated markets through high-quality generic products,' the company said in a press release. Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information. Ahmedabad Plane Crash Aditya Bhagchandani serves as the Senior Editor and Writer at Business Upturn, where he leads coverage across the Business, Finance, Corporate, and Stock Market segments. With a keen eye for detail and a commitment to journalistic integrity, he not only contributes insightful articles but also oversees editorial direction for the reporting team.
Business Upturn
30-05-2025
- Business
- Business Upturn
Marksans Pharma's subsidiary Relonchem gets UK MHRA approval for Metformin Hydrochloride Oral Solution
By Aman Shukla Published on May 30, 2025, 09:24 IST Marksans Pharma Limited has announced that its wholly owned UK subsidiary, Relonchem Limited, has received Marketing Authorization from the UK Medicines and Healthcare Products Regulatory Agency (MHRA) for Metformin Hydrochloride 500mg/5ml Oral Solution. This regulatory approval enables Relonchem to market and distribute the product in the UK. Metformin Hydrochloride is a widely prescribed medication used for the management of type 2 diabetes, particularly in patients who require oral liquid formulations due to difficulty in swallowing tablets. In the exchange filing, the company shared, 'Marksans Pharma Limited (Reuters: Bloomberg: MRKS IN; NSE: MARKSANS; BSE: 524404) hereby announces that its wholly owned subsidiary Relonchem Limited has received Marketing Authorization for the product Metformin Hydrochloride 500mg/ 5 ml Oral Solution from UK Medicines & Healthcare Products Regulatory Agency.' This approval marks a significant milestone for Marksans Pharma as it continues to strengthen its presence in regulated markets like the UK. The company's focus on expanding its product portfolio with value-added generic formulations aligns with its strategic growth vision. Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at
Business Upturn
15-05-2025
- Business
- Business Upturn
Marksans Pharma's UK subsidiary Relonchem gets UKMHRA nod for Gabapentin oral solution
By News Desk Published on May 15, 2025, 09:26 IST Marksans Pharma Limited announced on May 15 that its wholly owned UK subsidiary, Relonchem Limited, has received Marketing Authorization from the UK Medicines and Healthcare Products Regulatory Agency (UKMHRA) for Gabapentin 50 mg/ml oral solution. The regulatory approval marks a significant addition to the company's neurology-focused portfolio in the UK market. Gabapentin is commonly prescribed for the treatment of nerve pain and epilepsy. Marksans Pharma, headquartered in Mumbai, is engaged in the research, manufacturing, and marketing of generic pharmaceutical formulations. Its facilities in India, the US, and the UK are approved by major global regulatory bodies including the USFDA, UKMHRA, and TGA Australia. The company's portfolio spans key therapeutic areas including cardiovascular, central nervous system (CNS), anti-diabetics, pain management, gastroenterology, and anti-allergy segments. Disclaimer: This article is for informational purposes only and does not constitute investment advice. Please consult your financial advisor before making any investment decisions. News desk at
